不同剂量的吡柔比星应用于急性髓系白血病治疗的临床效果分析

目的探讨不同剂量的吡柔比星应用于急性髓系白血病治疗的临床疗效。方法入选2008年2月~2011年9月在我院就诊的急性髓系白血病患者113例,根据患者住院期间用药的不同将其分为对照组(n=57)和观察组(n=56),两组患者均给予TA化疗方案,对照组患者给予吡柔比星20 mg/(m2.d),而观察组患者给予吡柔比星40 mg/(m2.d),比较两组患者临床疗效和不良反应。结果观察组患者完全缓解率、总有效率分别为39.3%、92.9%显著高于对照组患者的29.8%、80.7%,差异均具有统计学意义(P<0.05);对照组患者未缓解率为19.3%,显著高于观察组患者的7.1%,差异具有统计学意义(P<0.05);观察组患者不良反应发生率为94.7%,高于对照组患者的78.9%,差异具有统计学意义(P<0.05)。结论大剂量的吡柔比星治疗急性髓系白血病可以提高患者的临床疗效,但是也会增加患者的不良反应的发生,因此在临床实践过程中应根据患者病情进行权衡使用。

The clinical effect of pirarubicin with different dose in acute myeloid leukemia patients

Objective To investigate the clinical effect of pirarubicin with different dose in acute myeloid leukemia pa- tients. Methods All 113 acute myeloid leukemia patients were enrolled from February 2008 to September 2011 in our hos- pital, they were divided into control group（n = 57） and observation group （r~= 56） according to the drug the chose while in hospital, the control group was given pirarubicin 20 mg/（m2＂ d） and the observation group was given 40 mg/（m2＂ d）,the clinical effect and untoward effect were compared between two groups. Results The complete response rate, overall re- sponse rate were 39.3%,92.9% in observation group and 29.8%, 80.7% in the control group, P 〈 0.05; the not ease rate was 19.3% in control group, was higher than 7.1% in observation group, P 〈 0.05; The incidence of untoward effect was 94.7%, was higher than 78.9% in control group. Conclusion Larger dose pirarubiein can increase the clinical effect in a- cute myeloid leukemia patients, but also increase the emerging of untoward effect, so the using of pirarubicin needs consid- ering the circumstance of patients.